

## Highlighted Research

### Tariffs

*A 5-minute read of what you need to know*

Proposed tariff policies could significantly impact the macroeconomic and market outlook. In this Highlighted Research, we curate cross-asset insights on potential market implications.

#### Global Research

##### Global Research <sup>AC</sup>

(1-212) 270-6000  
global.research@jpmresearchmail.com

##### Samantha Azzarello

(1-212) 648-2948  
samantha.m.azzarello@jpmorgan.com  
J.P. Morgan Securities LLC

**See page 15 for analyst certification and important disclosures.**

J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

## US Tariff Policies: Executive Authority

Higher tariffs to support US manufacturing are a key policy plank of Former President Trump's campaign, having mentioned two possible policies: a 60% tariff on all Chinese imports and a 10% universal tariff on all imports. Other proposals have included a 100% tariff on auto production in Mexico by Chinese automakers. Our analysts point out that "Trump tariffs were not abandoned but enhanced under the Biden administration, who left in place most of Trump's China trade policies, including tariffs, and doubled down with export controls."

Although estimates of the market impacts from proposed tariffs exist, our Global Equity Strategy team indicates that initial effects "would be offset by second and third order effects of their implementation." Our U.S. Economics team also notes that transitioning from a static to a dynamic calculation could significantly alter the results. While the composition of Congress is essential for fiscal and tax policy, tariffs remain front and center due to their potential implementation through Executive Authority.

### *Executive Authority*

Our Government Relations team emphasizes the need to distinguish between actions that can be taken through executive authority and those requiring congressional or legal support. The Executive Branch has considerable scope to impose sanctions through:

- **Section 301** of the Trade Act grants the President authority to investigate and address unfair trade practices by foreign countries, which includes the ability to impose tariffs.
  - This includes investigating unfair trade practices including subsidies, dumping and intellectual property theft.

While **Section 301 is a main tool for investigating and addressing unfair global trade practices**, **Section 302 provides additional power** to the President on other trade issues.

- **Section 302** includes addressing issues of national security and currency manipulation.
  - Tariffs can be imposed to protect US national security interests and address currency manipulation by foreign governments.
- **Section 232** allows the President to impose tariffs if the Department of Commerce concludes that imports of a particular product(s) threaten U.S. national security. To note, **Trump used this in the first term to put tariffs on steel and aluminum imports**.
  - Our analysts note that 232 will "likely see more use, as national security concerns have increased on everything from biotech to titanium sponge to electric vehicles."

Other available channels for imposing tariffs include:

- **IEEPA**, the International Economic Powers Act, gives the President broad authority to impose tariffs and other measures on countries. The statute is so broad that unlike 201, 232, or 301, it is not limited to specific products or countries.
- **Section 201** allows the President to impose temporary tariffs, if the U.S. International Trade Commission determines that a surge in imports is a substantial cause or threat of serious injury to a U.S. industry.

### *Congressional Support*

Of note, there are some proposed policies which may require legal basis or support of Congress. While the President can implement tariffs under the Sections outlined above, "that authority is not unlimited," and **new trade laws or even significant changes to existing laws likely require congressional support and action**. While scope under Section 301 could be subject to legal challenges, the team points out that the "courts give the President a great deal of freedom to use these authorities." **While there have been several legal challenges to the Trump 301 tariffs over the years, so far the courts have sided with the executive branch.**

***Role of USTR***

Furthermore, the Office of the United States Trade Representative (USTR) plays a crucial role in Section 301 related activity—conducting investigations and analysis, and making recommendations to the President.

See [REPLAY US Policy Issues: International Trade](#) (Michael Feroli | June 27, 2024)

## Macroeconomic Impacts

### *US Growth and Inflation*

Michael Feroli, Chief US Economist, points out that [while](#) “the Biden administration hasn’t been a vocal advocate of free trade—leaving intact the Trump tariffs on Chinese imports and recently selectively increasing tariffs further on some Chinese products—a second Trump administration would be much more protectionist” than a second Democratic administration. At the macro level, higher tariffs would “likely contribute to inflation.” Looking to the recent past Feroli [notes](#):

- “The Trump 1.0 tariffs increased the trade-weighted average tariff rate from around 1.5% to just over 3%.
- If this all fell on consumers it would have raised the basket of consumer prices by around 0.3%.
- Evidence from that period suggests that there was less than complete pass-through to consumer prices, suggesting retailers and other businesses swallowed some of the higher tariffs.
- On the other hand, there is also evidence that domestic producers used some of the increase in market power to push through higher prices.”


Extrapolating that reasoning with current proposals [suggests](#):

- A “**60% tariff on all Chinese imports** would **raise the price level 1.1%**, while a **10% universal tariff** would **increase the price level by 1.5%**.
- While shifting from a static to a dynamic calculation would likely change the results for the Chinese tariff proposal more dramatically, as it **may be easier to substitute away from China to other low-cost producers** than to substitute away from imported products altogether.”

The impacts to US growth are less clear, noting that “**in standard models the economic growth impact of tariffs is surprisingly small**,” however this may reflect that “trade models don’t capture intangibles like policy uncertainty” with Feroli emphasizing, “significant uncertainty attends to estimates of the impact on growth.” This bore out in 2018, with our Global Economics team [noting](#) “**large adverse effects to business confidence which led to a sharp slowing in capital spending**.”

In the latest [GDW](#), Bruce Kasman, Chief Global Economist, notes that “trade policy is the main channel by which the US election could generate a global common shock.” With analysis in the October World Economic Outlook (WEO) modelling the implementation of a “10% rise in US tariffs next year that generates retaliation elsewhere... the combined effects of these shocks are estimated to **depress global GDP 0.7%-pt by 2026 when they are reinforced by a negative shock to business sentiment**.”

Figure 1: Global (ex. China) business confidence, investment and IP



Source: National statistical agencies, J.P. Morgan.

### ***Fiscal Implications and Treasury Funding***

Jay Barry, Head of Global Rates, notes that with respect to government finances, **tariff revenues would only partially offset a full extension of the Tax Cut and Jobs Act (TCJA)**. While Congressional support would be needed to pass a TCJA extension, a red sweep scenario would “probably be the most significant from a funding perspective,” noting:

- The net impact of extending TCJA would forego over \$4tn in revenue over the next decade, with an additional \$600bn in interest expense, **offset in part by ~\$2tn in tariff revenue**.
- Potential added upward pressure on the deficit, which briefly captured market participants’ attention last fall, could resurface, driving the Treasury curve bearishly steeper.

Any proposal to use tariff revenues to fund an extension of the TCJA is expected to leave “**a net deficit of an additional ~\$2.5 trillion over the next decade**” versus baselines. However, Barry notes, overall “the Treasury Department has put itself in a great position with respect to its long-term funding needs” as:

- “Between August of last year and May of this year, sharply increased long-duration auction sizes, with net issuance of Treasury coupons in calendar year 2024 going to be ~\$800 billion larger than last year alone.
- If we look at the perspective baseline from the CBO, and the potential outcomes from the presidential election, it seems like the Treasury Department is in very firm footing with respect to its long-term issuance needs through probably the latter part of calendar year 2025.”

After that, Barry cautions, “there is a bigger issue which we’ve written about pretty significantly, that in this baseline, **Treasury is underfunded by ~\$3.3 trillion in the back half of the 2020s, assuming those baseline budget deficit expectations.** It’s going to require at some point **another series of pretty large increases to auction sizes** but the earliest that we could potentially see that would be next summer or next fall.”

## Market Implications

### FX

Meera Chandan, Co-head of Global FX Strategy, [emphasizes](#) the “**tariff channel is the foremost risk for the FX space**—reflecting both the White House’s discretion over its usage, as well as the **various pass-throughs to FX**—competitiveness adjustments, drags on global growth, etc.” The team is [estimating](#) a “**4-6% USD appreciation if universal 10% tariffs were to be introduced**” while the “expanding list of fiscal priorities for both sides could in certain scenarios unlock more USD upside than we had originally envisioned,” [noting](#):

- “The most bullish USD outcome could thus become greater fiscal spending and policies alongside tariffs, which could foster an **intensified backdrop of US exceptionalism**.”
- USD does best in a Red Sweep (EUR/USD 1.00-1.02; USD/CNY 7.40), while a Democrat victory should see temporary USD weakening.”

Looking at global FX implications of tariffs and trade conflicts, Arindam Sandilya, Co-Head of Global FX Strategy, [highlights](#):

- **EUR:** Two-sided risks from elections. Downside if negative domestic backdrop worsens on trade confrontation. **Avoiding tariffs should boost the currency on sentiment**, but this won’t change structural drags which eventually should still dominate.
- **CNY:** Straightforward underperformer in trade conflict—but downside may meet resistance from 1) PBoC reaction function, 2) changing elasticities of exports, 3) foreign investor UW across assets. Equally, **PBoC likely will smooth CNY strength if tariffs are avoided**, even as the currency should be aided by seasonal end-4Q/early-1Q exporter USD conversion and **potential greater foreign equity inflows** if the tariff threat does not materialize.
- **CHF:** Top performer in 2019 trade war; anti-cyclical properties amplified by Euro-area-specific vulnerabilities.
- **JPY:** Should take its cue from direction of Fed pricing and global growth impact, rather than broader USD/Asia direction. **Combination of tariffs and Fed easing would result in yen strength as in 2019, in our view.**

While looking at broad USD impacts of Tariffs under various election [outcomes](#):

- **Republican sweep:** Broadly stronger—US exceptionalism, amplified by tariffs and fiscal spending, broad USD strength.
- **Trump with split congress:** Stronger vs. EMU/China-linked, commodity FX—tariff risk weighs on US and more so for ex-US growth.
- **Harris with split congress:** Broadly weaker, temporarily—limited policy impact, but relief on tariffs.
- **Democratic sweep:** Broadly weaker, temporarily, but smaller than in split congress—tariff risk dissipates, but fiscal can ultimately revive modest US exceptionalism.

See [US Elections: A Roadmap for FX and Hedges](#) (Meera Chandan, Arindam Sandilya et al. | October 11, 2024)

Figure 2: Scenario analysis of FX impacts

	Republican sweep	Trump w/ split congress	Harris w/ split congress	Dem sweep
<b>Regime</b>	US exceptionalism, amplified by tariffs + fiscal; broad USD strength	Tariff risk weighs on US and more so for ex-US growth; defensive USD smile	Limited policy impact, but relief on tariffs - Temporarily in the middle of the USD smile, short vol	Middle of the dollar smile temporarily as tariff risk dissipates, but fiscal can ultimately revive modest US exceptionalism
<b>USD TWI (JBDNUSD)</b>	7%	3%	-5%	-4%
<b>EUR vs. USD</b>	1.00-1.02	1.05	1.13-1.15	1.12-1.14
<b>SEK</b>	11.50	10.90	9.80	9.90
<b>CNY</b>	7.40	7.30	6.90	6.95
<b>AUD</b>	0.63	0.65	0.70	0.69
<b>JPY</b>	155-160	138-143	140-145	145-150
<b>CAD</b>	1.44	1.42	1.32	1.34
<b>EUR/CHF</b>	0.90	0.89	0.97	0.98
<b>EUR/GBP</b>	0.80	0.82	0.86	0.85
<b>USD</b>	Broadly stronger	Stronger vs. EMU/China-linked, commodity FX	Broadly weaker, temporarily	Broadly weaker, temporarily, but smaller magnitude than in split congress
<b>Relative underperformers</b>	Commodity FX CNH, Cyclical Asia High beta euro bloc, EUR CAD, MXN vs. USD JPY	Commodity FX CNH, Cyclical Asia High beta euro bloc, EUR CAD, MXN vs. USD	USD CHF vs. EUR	USD Funders more vulnerable; CHF vs. EUR JPY vs. USD, crosses
<b>Relative outperformers</b>	USD CHF vs. EUR CAD vs. other high beta	USD Funders more resilient; CHF vs. EUR JPY CAD vs. other high beta	Commodity FX CNH, Cyclical Asia High beta euro bloc, EUR	Commodity FX CNH, Cyclical Asia High beta euro bloc, EUR

Source: J.P. Morgan Global FX Strategy.

## Equities

Zooming out, the Global Equity Strategy team notes that “unlike past election cycles, when the debate focused on which set of policies are more positive for equity markets, the current scenarios seem to be more neutral, with the potential for negative outcomes.” The team notes that overall:

- “View **‘Blue Top’ with gridlock** as the most neutral outcome in the short/medium term, as it would limit changes to existing policies passed under the current administration and limit the implementation of new, and possibly volatile ones, though risks remain around unilateral executive and/or agency action.
- A **‘Red Top’ scenario**, that raises existing tariffs on China and imposes a universal tariff on all other trading partners would have significant implications on the growth and inflation outlook, and as a result on US equities across sectors/styles.”

The team notes that “some of the tariff sensitive stocks are not really pricing in risk of tariffs,” while these policies will likely have “significant impacts” on equity markets, especially those companies sensitive to revenue exposure in China. Mislav Matejka, Global Equity Strategist, [notes](#) that the bond market reaction will be key, “if yields respond more negatively to the reflationary policies this time around, the equity market could be constrained. This could also be the case if trade is the first policy priority.”



US Equity Strategist Kamal Tamboli provides context on current tariffs, adding:

- “The US is not currently fully tariffing China. Based on the different schedules, tariffs stand somewhere between 7.5% to 25% on a little over \$300 billion worth of goods. Moreover, there’s a number of carve-outs. So for example, iPhones are not currently subject to US tariffs on Chinese imports.
- The 60% tariff proposal is meaningful because it not only presents a material escalation, but it could also mean that more goods come into scope.”

On the potential market impact, the team highlights that if former President Trump is elected and he’s able to implement much of this agenda, it could be significant as:

- “There is risk of retaliation from China for tariff increases from the US, impacting US corporations that import heavily from China, or are heavily integrated into the Chinese supply chain.
- We’ve primarily been semiconductor and MAG- 7 led, with narrow leadership and a lot of right-tail momentum crowding. While we’ve had pullbacks, you could see a more substantial fundamentally led unwind in some of these very popular trades if these tariffs are implemented.
- We know that these areas have been sensitive in the past to incremental news on changes in tariff policies, and we think there will be increasing, not decreasing sensitivity if trade ends up becoming the top policy agenda.”

Overall, Tamboli notes, “we think that this is something that the equity market hasn’t really fully priced in yet in terms of the risk. If anything, given the way the betting odds and different polling data has moved, markets have been faster to re-price upside than potential downside from broad-based tariffs in Red Sweep or Red Divided Government scenarios.”

See [Equity Strategy: Regional trades](#) (Mislav Matejka et al. | October 28, 2024)

### *Credit*

Our Credit team notes potential impacts of higher tariffs, with Eric Beinstein, Head of U.S. High Grade Credit Research, citing the “macro and micro implications of proposed policies. Overall we believe the macro impacts/risks are more consequential for credit than the micro.” For instance, “**if tariffs lead to higher inflation and therefore higher yields, this could be supportive for spreads, unless it comes with greater UST volatility and fears of fiscal sustainability.**” Around relative impacts, the team notes that high tariffs may favor HY over HG:

- “The HG market is heavily weighted towards multi-nationals and 27% of the JULI is non-US companies so **trade policy can be a material factor for HG credit.**
- The HY and LL markets are more domestically focused, so an expectation of higher tariffs may lead to relative outperformance of HY vs HG.
- For context, more than 90% of the JPMorgan High-Yield Bond index consists of Domestic corporates and we estimate that less than 15% of revenues are generated abroad.”

With respect to sector impacts, Tarek Hamid, Head of J.P. Morgan’s North American Corporate Credit Research, points out that “while we can surmise the general potential impacts of certain policy proposals, the devil is very much in the details as to how a particular piece of legislation could eventually come together and impact specific companies.” The team is watching “**the impacts of tariffs on different parts of the retail sector, Tech and commodities, and a pro-domestic production agenda in Energy,**” with our sector analysts focused on the “potential for more M&A.”

See [US Credit Impacts of Trump’s Economic Proposals](#) (Eric Beinstein, Tarek Hamid, Kabir Caprihan et al. | July 30, 2024)

### *Commodities*

For Commodities markets, Natasha Kaneva, Head of Commodities Research notes the varied impact of Tariffs [as](#):

- **Gold stands out as a beneficiary** if certain structurally bullish drivers “remain intact” including “concerns of complacency

over the rise in fiscal debt, tariffs, and trade retaliations as well as broad ‘America First’ rhetoric.”

- In base metals, “**significant tariff escalation risks undercutting a bullish fundamental copper set up in 2025**,” caveating, however, “a Republican majority that prioritizes other growth supportive initiatives first (over Tariffs) could present a runway for further base metals outperformance in 2025.”

The Commodities team [emphasizes](#) that “**sequencing of policy priorities will be key**,” as a “the price trajectory of industrial metals will largely depend on the order of policy initiatives (tax cut extensions, deregulation vs tariffs),” with outcomes being influenced by the composition of Congress.

See [Global Commodities: 2024 US Election Watch – Reassessing implications for Commodities under a Red Wave](#) (Natasha Kaneva et al. | July 17, 2024)

[Global Commodities: 2024 US Election Watch – Implications for Commodities](#) (Natasha Kaneva et al. | May 7, 2024)

*For investors looking to manage exposure to escalating US-China tariffs, see US companies with high direct revenue exposure to China (JPAMCREV <Index>) and US Importers (JPAMUSIM <Index>).*

*See [Global Thematic Strategy: Key Upcoming Elections, Equity Implications, Policy-Linked Stock Ideas](#) (Dubravko Lakos-Bujas et al. | May 7, 2024)*

*Note: J.P. Morgan Research does not provide research coverage of these basket and investors should not expect continuous analysis or additional reports relating to them.*

## China Impacts

Jonny Goulden, Head of EM Fixed Income Strategy, and Jahangir Aziz, Head of EM Economic Research, [note](#) the “impact of tariff war 2.0 (from 25% to 60% tariff) could be 40% higher than the impact of tariff war 1.0, if only considering the magnitude of tariff increase. In reality, the outcome could be more complicated,” as:

- “The **economic impact could be much smaller given that China’s share in US imports has declined by one third** and the share of China exports to the US in China’s total exports has declined by nearly one fourth, from 2018 to 2023.
- Both direct and indirect impacts could tend to be smaller due to the **weakened bilateral trade relationship**.
- However, if tariff war 2.0 involves a spillover of tariff increases by other trading partners or US tariff increases on goods produced in a third country by Chinese companies, the impact could be more disruptive.”

Furthermore, our analysts point out that “neither party is seeking a significant rapprochement with China on trade, which points to additional tariff and non-tariff barriers to trade in the coming years.”

### *2018 Episode*


The EM team [estimates](#) that the **economic cost of the 2018 US tariffs on the Chinese economy was about 1%-pt of GDP**—with a 0.3%pt direct impact (via export channel) and 0.7%pt indirect impact (via consumption, income and sentiment). In that episode, China’s responses included three things:

1. A retaliatory tariff increase on imports from the US (average tariffs increased by 16.2%pts for the US imports of Chinese goods and by 13.1%pts for China imports of US goods).
2. CNY depreciation with a coefficient of around 0.5 (1% CNY depreciation against USD in response to 2% tariff increase).
3. Transshipment or overseas investment in a third country, e.g. in ASEAN or Latam.

Overall, “these measures could still be adopted by the Chinese government if a tariff war 2.0 scenario materializes. In addition, **China may use export controls in strategically important metals** (e.g. rare earth, graphite, etc.) as **potential retaliatory measures**.”

Figure 3: US imports by origin

% of total US imports



Source: CEIC, J.P.Morgan.

## FX

Outlining the potential [impacts](#) to CNY, Patrick Locke, Senior FX Strategist, highlights that “CNY should still net weaken in the event additional tariffs are imposed, but the ex-ante setup is different now vs 2018” as:

- (1) The entry point is different now—the shock value of trade conflict is diminished vs 2018, and China still carries a 20% effective tariff rate on exports to the US.
- (2) The tariff-rate regime governing USD/CNY in 2018-2019 has since evolved despite no tariff relief.
- (3) Positioning and valuations are more supportive now for CNY, while foreigners have liquidated positions at a near-record pace this year.

## Knock-on effects

The team [emphasizes](#) that a further rise in US-China trade tensions would likely accelerate supply chain relocations, noting:

- “Alongside the decline in China’s exports to G-3 countries, the past years have seen significant gains in exports to Africa, ASEAN and Latam.
- If a tariff war 2.0 materializes ASEAN countries and Mexico will likely remain key beneficiaries of trade relocation due to supportive policies, cost competitiveness, industrial developments and linkages to existing manufacturing

hubs.

- India should also benefit but needs to draw on its large pool of labor to develop its manufacturing sectors.”

## References

### *Economics*

[US: Election news leads to small rise in sentiment](#) (Abiel Reinhart | August 16, 2024)

[US: Economic policy implications of the election](#) (Michael Feroli | June 28, 2024)

[Politics and monetary independence](#) (Joseph Lupton et al. | August 1, 2024)

[Emerging Markets Outlook and Strategy for 2H24](#) (Luis Oganés, Jonny Goulden, Jahangir Aziz et al. | June 6, 2024)

### *Rates*

[Elections – The Fed – US Rates and the Municipal Markets](#) (Peter DeGroot et al. | August 2024)

### *FX*

[US Elections: A Roadmap for FX and Hedges](#) (Meera Chandan, Arindam Sandilya et al. | October 11, 2024)

[US Elections & FX: Mapping transmission from potential policies to USD](#) (Patrick Locke | February 5, 2024)

[FX Markets Weekly: USD down but not out\(age\)](#) (Meera Chandan et al. | July 19, 2024)

[FX Markets Weekly: The Fed, tariffs and other sources of dollar risk premia](#) (Meera Chandan et al. | February 5, 2024)

### *Equity Strategy*

[Global Thematic Strategy: Key Upcoming Elections, Equity Implications, Policy-Linked Stock Ideas](#) (Dubravko Lakos-Bujas et al. | May 7, 2024)

### *Credit*

[US Credit Impacts of Trump's Economic Proposals](#) (Eric Beinstein, Tarek Hamid, Kabir Caprihan et al. | July 30, 2024)

### *Commodities*

[Oil Weekly: Election Trade](#) (Natasha Kaneva, Prateek Kedia et al. | July 30, 2024)

[Global Commodities: 2024 US Election Watch – Reassessing Implications for Commodities under a Red Wave](#) (Natasha Kaneva et al. | July 17, 2024)

[Global Commodities: 2024 US Election Watch – Implications for Commodities](#) (Natasha Kaneva et al. | May 7, 2024)

## Disclosures

**Analyst Certification:** The Research Analyst(s) denoted by an "AC" on the cover of this report certifies (or, where multiple Research Analysts are primarily responsible for this report, the Research Analyst denoted by an "AC" on the cover or within the document individually certifies, with respect to each security or issuer that the Research Analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect the Research Analyst's personal views about any and all of the subject securities or issuers; and (2) no part of any of the Research Analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the Research Analyst(s) in this report. For all Korea-based Research Analysts listed on the front cover, if applicable, they also certify, as per KOFIA requirements, that the Research Analyst's analysis was made in good faith and that the views reflect the Research Analyst's own opinion, without undue influence or intervention.

All authors named within this report are Research Analysts who produce independent research unless otherwise specified. In Europe, Sector Specialists (Sales and Trading) may be shown on this report as contacts but are not authors of the report or part of the Research Department.

## Important Disclosures

**Company-Specific Disclosures:** Important disclosures, including price charts and credit opinion history tables, are available for compendium reports and all J.P. Morgan-covered companies, and certain non-covered companies, by visiting <https://www.jpmm.com/research/disclosures>, calling 1-800-477-0406, or e-mailing [research.disclosure.inquiries@jpmorgan.com](mailto:research.disclosure.inquiries@jpmorgan.com) with your request.

### Explanation of Equity Research Ratings, Designations and Analyst(s) Coverage Universe:

J.P. Morgan uses the following rating system: Overweight (over the duration of the price target indicated in this report, we expect this stock will outperform the average total return of the stocks in the Research Analyst's, or the Research Analyst's team's, coverage universe); Neutral (over the duration of the price target indicated in this report, we expect this stock will perform in line with the average total return of the stocks in the Research Analyst's, or the Research Analyst's team's, coverage universe); and Underweight (over the duration of the price target indicated in this report, we expect this stock will underperform the average total return of the stocks in the Research Analyst's, or the Research Analyst's team's, coverage universe. NR is Not Rated. In this case, J.P. Morgan has removed the rating and, if applicable, the price target, for this stock because of either a lack of a sufficient fundamental basis or for legal, regulatory or policy reasons. The previous rating and, if applicable, the price target, no longer should be relied upon. An NR designation is not a recommendation or a rating. In our Asia (ex-Australia and ex-India) and U.K. small- and mid-cap Equity Research, each stock's expected total return is compared to the expected total return of a benchmark country market index, not to those Research Analysts' coverage universe. If it does not appear in the Important Disclosures section of this report, the certifying Research Analyst's coverage universe can be found on J.P. Morgan's Research website, <https://www.jpmorganmarkets.com>.

### J.P. Morgan Equity Research Ratings Distribution, as of October 05, 2024

	Overweight (buy)	Neutral (hold)	Underweight (sell)
J.P. Morgan Global Equity Research Coverage*	49%	38%	13%
IB clients**	50%	46%	38%
JPMS Equity Research Coverage*	46%	41%	13%
IB clients**	71%	67%	54%

\*Please note that the percentages may not add to 100% because of rounding.

\*\*Percentage of subject companies within each of the "buy," "hold" and "sell" categories for which J.P. Morgan has provided investment banking services within the previous 12 months.

For purposes of FINRA ratings distribution rules only, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold rating category; and our Underweight rating falls into a sell rating category. Please note that stocks with an NR designation are not included in the table above. This information is current as of the end of the most recent calendar quarter.

**Equity Valuation and Risks:** For valuation methodology and risks associated with covered companies or price targets for covered companies, please see the most recent company-specific research report at <http://www.jpmorganmarkets.com>, contact the primary analyst or your J.P. Morgan representative, or email [research.disclosure.inquiries@jpmorgan.com](mailto:research.disclosure.inquiries@jpmorgan.com). For material information about the proprietary models used, please see the Summary of Financials in company-specific research reports and the Company Tearsheets, which are available to download on the company pages of our client website, <http://www.jpmorganmarkets.com>. This report also sets out within it the material underlying assumptions used.

A history of J.P. Morgan investment recommendations disseminated during the preceding 12 months can be accessed on the Research & Commentary page of <http://www.jpmorganmarkets.com> where you can also search by analyst name, sector or financial instrument.

### Explanation of Emerging Markets Sovereign Research Ratings System and Valuation & Methodology:

**Ratings System:** J.P. Morgan uses the following issuer portfolio weightings for Emerging Markets Sovereign Research: Overweight (over the next three months, the recommended risk position is expected to outperform the relevant index, sector, or benchmark credit returns); Marketweight (over the next three months, the recommended risk position is expected to perform in line with the relevant index, sector, or



benchmark credit returns); and Underweight (over the next three months, the recommended risk position is expected to underperform the relevant index, sector, or benchmark credit returns). NR is Not Rated. In this case, J.P. Morgan has removed the rating for this security because of either legal, regulatory or policy reasons or because of lack of a sufficient fundamental basis. The previous rating no longer should be relied upon. An NR designation is not a recommendation or a rating. NC is Not Covered. An NC designation is not a rating or a recommendation. Recommendations will be at the issuer level, and an issuer recommendation applies to all of the index-eligible bonds at the same level for the issuer. When we change the issuer-level rating, we are changing the rating for all of the issues covered, unless otherwise specified. Ratings for quasi-sovereign issuers in the EMBIG may differ from the ratings provided in EM corporate coverage.

**Valuation & Methodology:** For J.P. Morgan's Emerging Markets Sovereign Research, we assign a rating to each sovereign issuer (Overweight, Marketweight or Underweight) based on our view of whether the combination of the issuer's fundamentals, market technicals, and the relative value of its securities will cause it to outperform, perform in line with, or underperform the credit returns of the EMBIGD index over the next three months. Our view of an issuer's fundamentals includes our opinion of whether the issuer is becoming more or less able to service its debt obligations when they become due and payable, as well as whether its willingness to service debt obligations is increasing or decreasing.

#### J.P. Morgan Emerging Markets Sovereign Research Ratings Distribution, as of October 5, 2024

	Overweight (buy)	Marketweight (hold)	Underweight (sell)
Global Sovereign Research Universe*	12%	79%	9%
IB clients**	88%	50%	50%

\*Please note that the percentages may not add to 100% because of rounding.

\*\*Percentage of subject issuers within each of the "Overweight," "Marketweight" and "Underweight" categories for which J.P. Morgan has provided investment banking services within the previous 12 months.

For purposes of FINRA ratings distribution rules only, our Overweight rating falls into a buy rating category; our Marketweight rating falls into a hold rating category; and our Underweight rating falls into a sell rating category. The Emerging Markets Sovereign Research Rating Distribution is at the issuer level. Issuers with an NR or an NC designation are not included in the table above. This information is current as of the end of the most recent calendar quarter.

#### Explanation of Credit Research Valuation Methodology, Ratings and Risk to Ratings:

J.P. Morgan uses a bond-level rating system that incorporates valuations (relative value) and our fundamental view on the security. Our fundamental credit view of an issuer is based on the company's underlying credit trends, overall creditworthiness and our opinion on whether the issuer will be able to service its debt obligations when they become due and payable. We analyze, among other things, the company's cash flow capacity and trends and standard credit ratios, such as gross and net leverage, interest coverage and liquidity ratios. We also analyze profitability, capitalization and asset quality, among other variables, when assessing financials. Analysts also rate the issuer, based on the rating of the benchmark or representative security. Unless we specify a different recommendation for the company's individual securities, an issuer recommendation applies to all of the bonds at the same level of the issuer's capital structure. We may also rate certain loans and preferred securities, as applicable. This report also sets out within it the material underlying assumptions used. We use the following ratings for bonds (issues), issuers, loans, and preferred securities: Overweight (over the next three months, the recommended risk position is expected to outperform the relevant index, sector, or benchmark); Neutral (over the next three months, the recommended risk position is expected to perform in line with the relevant index, sector, or benchmark); and Underweight (over the next three months, the recommended risk position is expected to underperform the relevant index, sector, or benchmark). J.P. Morgan Emerging Markets Sovereign Research uses Marketweight, which is equivalent to Neutral. NR is Not Rated. In this case, J.P. Morgan has removed the rating for this particular security or issuer because of either a lack of a sufficient fundamental basis or for legal, regulatory or policy reasons. The previous rating no longer should be relied upon. An NR designation is not a recommendation or a rating. NC is Not Covered. An NC designation is not a rating or a recommendation. For CDS, we use the following rating system: Long Risk (over the next three months, the credit return on the recommended position is expected to exceed the relevant index, sector or benchmark); Neutral (over the next three months, the credit return on the recommended position is expected to match the relevant index, sector or benchmark); and Short Risk (over the next three months, the credit return on the recommended position is expected to underperform the relevant index, sector or benchmark).

#### J.P. Morgan Credit Research Ratings Distribution, as of October 05, 2024

	Overweight (buy)	Neutral (hold)	Underweight (sell)
Global Credit Research Universe*	27%	57%	16%
IB clients**	64%	61%	64%

\*Please note that the percentages may not add to 100% because of rounding.

\*\*Percentage of subject companies within each of the "Overweight," "Neutral" and "Underweight" categories for which J.P. Morgan has provided investment banking services within the previous 12 months.

For purposes of FINRA ratings distribution rules only, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold rating category; and our Underweight rating falls into a sell rating category. The Credit Research Rating Distribution is at the issuer level. Issuers with an NR or an NC designation are not included in the table above. This information is current as of the end of the most recent calendar quarter.



**Analysts' Compensation:** The research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues.

**Registration of non-US Analysts:** Unless otherwise noted, the non-US analysts listed on the front of this report are employees of non-US affiliates of J.P. Morgan Securities LLC, may not be registered as research analysts under FINRA rules, may not be associated persons of J.P. Morgan Securities LLC, and may not be subject to FINRA Rule 2241 or 2242 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

**Company-Specific Disclosures:** Important disclosures, including price charts and credit opinion history tables, are available for compendium reports and all J.P. Morgan-covered companies, and certain non-covered companies, by visiting <https://www.jpmm.com/research/disclosures>, calling 1-800-477-0406, or e-mailing [research.disclosure.inquiries@jpmorgan.com](mailto:research.disclosure.inquiries@jpmorgan.com) with your request.

## Other Disclosures

---

J.P. Morgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide.

**UK MIFID FICC research unbundling exemption:** UK clients should refer to [UK MIFID Research Unbundling exemption](#) for details of J.P. Morgan's implementation of the FICC research exemption and guidance on relevant FICC research categorisation.

All research material made available to clients are simultaneously available on our client website, J.P. Morgan Markets, unless specifically permitted by relevant laws. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research material available on a particular stock, please contact your sales representative.

Any long form nomenclature for references to China; Hong Kong; Taiwan; and Macau within this research material are Mainland China; Hong Kong SAR (China); Taiwan (China); and Macau SAR (China).

J.P. Morgan Research may, from time to time, write on issuers or securities targeted by economic or financial sanctions imposed or administered by the governmental authorities of the U.S., EU, UK or other relevant jurisdictions (Sanctioned Securities). Nothing in this report is intended to be read or construed as encouraging, facilitating, promoting or otherwise approving investment or dealing in such Sanctioned Securities. Clients should be aware of their own legal and compliance obligations when making investment decisions.

Any digital or crypto assets discussed in this research report are subject to a rapidly changing regulatory landscape. For relevant regulatory advisories on crypto assets, including bitcoin and ether, please see <https://www.jpmorgan.com/disclosures/cryptoasset-disclosure>.

The author(s) of this research report may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so.

**Exchange-Traded Funds (ETFs):** J.P. Morgan Securities LLC ("JPMS") acts as authorized participant for substantially all U.S.-listed ETFs. To the extent that any ETFs are mentioned in this report, JPMS may earn commissions and transaction-based compensation in connection with the distribution of those ETF shares and may earn fees for performing other trade-related services, such as securities lending to short sellers of the ETF shares. JPMS may also perform services for the ETFs themselves, including acting as a broker or dealer to the ETFs. In addition, affiliates of JPMS may perform services for the ETFs, including trust, custodial, administration, lending, index calculation and/or maintenance and other services.

**Options and Futures related research:** If the information contained herein regards options- or futures-related research, such information is available only to persons who have received the proper options or futures risk disclosure documents. Please contact your J.P. Morgan Representative or visit <https://www.theocc.com/components/docs/riskstoc.pdf> for a copy of the Option Clearing Corporation's Characteristics and Risks of Standardized Options or [http://www.finra.org/sites/default/files/Security\\_Futures\\_Risk\\_Disclosure\\_Statement\\_2018.pdf](http://www.finra.org/sites/default/files/Security_Futures_Risk_Disclosure_Statement_2018.pdf) for a copy of the Security Futures Risk Disclosure Statement.

**Changes to Interbank Offered Rates (IBORs) and other benchmark rates:** Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: [https://www.jpmorgan.com/global/disclosures/interbank\\_offered\\_rates](https://www.jpmorgan.com/global/disclosures/interbank_offered_rates)

**Private Bank Clients:** Where you are receiving research as a client of the private banking businesses offered by JPMorgan Chase & Co. and its subsidiaries ("J.P. Morgan Private Bank"), research is provided to you by J.P. Morgan Private Bank and not by any other division of J.P. Morgan, including, but not limited to, the J.P. Morgan Corporate and Investment Bank and its Global Research division.

**Legal entity responsible for the production and distribution of research:** The legal entity identified below the name of the Reg AC Research Analyst who authored this material is the legal entity responsible for the production of this research. Where multiple Reg AC Research Analysts authored this material with different legal entities identified below their names, these legal entities are jointly responsible for the production of this research. Research Analysts from various J.P. Morgan affiliates may have contributed to the production of this material but may not be licensed to carry out regulated activities in your jurisdiction (and do not hold themselves out as being able to do so). Unless otherwise stated below, this material has been distributed by the legal entity responsible for production. If you have any queries, please contact the relevant

Research Analyst in your jurisdiction or the entity in your jurisdiction that has distributed this research material.

#### Legal Entities Disclosures and Country-/Region-Specific Disclosures:

**Argentina:** JPMorgan Chase Bank N.A Sucursal Buenos Aires is regulated by Banco Central de la República Argentina ("BCRA"- Central Bank of Argentina) and Comisión Nacional de Valores ("CNV"- Argentinian Securities Commission - ALYC y AN Integral N°51). **Australia:** J.P. Morgan Securities Australia Limited ("JPMSAL") (ABN 61 003 245 234/AFS Licence No: 238066) is regulated by the Australian Securities and Investments Commission and is a Market Participant of ASX Limited, a Clearing and Settlement Participant of ASX Clear Pty Limited and a Clearing Participant of ASX Clear (Futures) Pty Limited. This material is issued and distributed in Australia by or on behalf of JPMSAL only to "wholesale clients" (as defined in section 761G of the Corporations Act 2001). A list of all financial products covered can be found by visiting <https://www.jpmm.com/research/disclosures>. J.P. Morgan seeks to cover companies of relevance to the domestic and international investor base across all Global Industry Classification Standard (GICS) sectors, as well as across a range of market capitalisation sizes. If applicable, in the course of conducting public side due diligence on the subject company(ies), the Research Analyst team may at times perform such diligence through corporate engagements such as site visits, discussions with company representatives, management presentations, etc. Research issued by JPMSAL has been prepared in accordance with J.P. Morgan Australia's Research Independence Policy which can be found at the following link: [J.P. Morgan Australia - Research Independence Policy](#). **Brazil:** Banco J.P. Morgan S.A. is regulated by the Comissão de Valores Mobiliários (CVM) and by the Central Bank of Brazil. Ombudsman J.P. Morgan: 0800-7700847 / 0800-7700810 (For Hearing Impaired) / [ouvidoria.jp.morgan@jpmorgan.com](mailto:ouvidoria.jp.morgan@jpmorgan.com). **Canada:** J.P. Morgan Securities Canada Inc. is a registered investment dealer, regulated by the Canadian Investment Regulatory Organization and the Ontario Securities Commission and is the participating member on Canadian exchanges. This material is distributed in Canada by or on behalf of J.P.Morgan Securities Canada Inc. **Chile:** Inversiones J.P. Morgan Limitada is an unregulated entity incorporated in Chile. **China:** J.P. Morgan Securities (China) Company Limited has been approved by CSRC to conduct the securities investment consultancy business. **Dubai International Financial Centre (DIFC):** JPMorgan Chase Bank, N.A., Dubai Branch is regulated by the Dubai Financial Services Authority (DFSA) and its registered address is Dubai International Financial Centre - The Gate, West Wing, Level 3 and 9 PO Box 506551, Dubai, UAE. This material has been distributed by JP Morgan Chase Bank, N.A., Dubai Branch to persons regarded as professional clients or market counterparties as defined under the DFSA rules. **European Economic Area (EEA):** Unless specified to the contrary, research is distributed in the EEA by J.P. Morgan SE ("JPM SE"), which is authorised as a credit institution by the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB). JPM SE is a company headquartered in Frankfurt with registered address at TaunusTurm, Taunustor 1, Frankfurt am Main, 60310, Germany. The material has been distributed in the EEA to persons regarded as professional investors (or equivalent) pursuant to Art. 4 para. 1 no. 10 and Annex II of MiFID II and its respective implementation in their home jurisdictions ("EEA professional investors"). This material must not be acted on or relied on by persons who are not EEA professional investors. Any investment or investment activity to which this material relates is only available to EEA relevant persons and will be engaged in only with EEA relevant persons. **Hong Kong:** J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong, and J.P. Morgan Broking (Hong Kong) Limited (CE number AAB027) is regulated by the Securities and Futures Commission in Hong Kong. JP Morgan Chase Bank, N.A., Hong Kong Branch (CE Number AAL996) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission, is organized under the laws of the United States with limited liability. Where the distribution of this material is a regulated activity in Hong Kong, the material is distributed in Hong Kong by or through J.P. Morgan Securities (Asia Pacific) Limited and/or J.P. Morgan Broking (Hong Kong) Limited. **India:** J.P. Morgan India Private Limited (Corporate Identity Number - U67120MH1992FTC068724), having its registered office at J.P. Morgan Tower, Off. C.S.T. Road, Kalina, Santacruz - East, Mumbai - 400098, is registered with the Securities and Exchange Board of India (SEBI) as a 'Research Analyst' having registration number INH000001873. J.P. Morgan India Private Limited is also registered with SEBI as a member of the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited (SEBI Registration Number - INZ000239730) and as a Merchant Banker (SEBI Registration Number - MB/INM000002970). Telephone: 91-22-6157 3000, Facsimile: 91-22-6157 3990 and Website: <http://www.jpmipl.com>. JPMorgan Chase Bank, N.A. - Mumbai Branch is licensed by the Reserve Bank of India (RBI) (Licence No. 53/ Licence No. BY.4/94; SEBI - IN/CUS/014/ CDSL : IN-DP-CDSL-444-2008/ IN-DP-NSDL-285-2008/ INBI00000984/ INE231311239) as a Scheduled Commercial Bank in India, which is its primary license allowing it to carry on Banking business in India and other activities, which a Bank branch in India are permitted to undertake. For non-local research material, this material is not distributed in India by J.P. Morgan India Private Limited. Compliance Officer: Spurthi Gadamsetty; [spurthi.gadamsetty@jpmchase.com](mailto:spurthi.gadamsetty@jpmchase.com); +912261573225. Grievance Officer: Ramprasadh K, [jpmipl.research.feedback@jpmorgan.com](mailto:jpmipl.research.feedback@jpmorgan.com); +912261573000.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

**Indonesia:** PT J.P. Morgan Sekuritas Indonesia is a member of the Indonesia Stock Exchange and is registered and supervised by the Otoritas Jasa Keuangan (OJK). **Korea:** J.P. Morgan Securities (Far East) Limited, Seoul Branch, is a member of the Korea Exchange (KRX). JPMorgan Chase Bank, N.A., Seoul Branch, is licensed as a branch office of foreign bank (JPMorgan Chase Bank, N.A.) in Korea. Both entities are regulated by the Financial Services Commission (FSC) and the Financial Supervisory Service (FSS). For non-macro research material, the material is distributed in Korea by or through J.P. Morgan Securities (Far East) Limited, Seoul Branch. **Japan:** JPMorgan Securities Japan Co., Ltd. and JPMorgan Chase Bank, N.A., Tokyo Branch are regulated by the Financial Services Agency in Japan. **Malaysia:** This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-X), which is a Participating Organization of Bursa Malaysia Berhad and holds a Capital Markets Services License issued by the Securities Commission in Malaysia. **Mexico:** J.P. Morgan Casa de Bolsa, S.A. de C.V. and J.P. Morgan Grupo Financiero are members of the Mexican Stock Exchange and are authorized to act as a broker dealer by the National Banking and Securities Exchange Commission. **New Zealand:** This material is issued and distributed by JPMSAL in New Zealand

only to "wholesale clients" (as defined in the Financial Markets Conduct Act 2013). JPMSAL is registered as a Financial Service Provider under the Financial Service providers (Registration and Dispute Resolution) Act of 2008. **Philippines:** J.P. Morgan Securities Philippines Inc. is a Trading Participant of the Philippine Stock Exchange and a member of the Securities Clearing Corporation of the Philippines and the Securities Investor Protection Fund. It is regulated by the Securities and Exchange Commission. **Singapore:** This material is issued and distributed in Singapore by or through J.P. Morgan Securities Singapore Private Limited (JPMS) [MDDI (P) 068/08/2024 and Co. Reg. No.: 199405335R], which is a member of the Singapore Exchange Securities Trading Limited, and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore), both of which are regulated by the Monetary Authority of Singapore. This material is issued and distributed in Singapore only to accredited investors, expert investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289 (SFA). This material is not intended to be issued or distributed to any retail investors or any other investors that do not fall into the classes of "accredited investors," "expert investors" or "institutional investors," as defined under Section 4A of the SFA. Recipients of this material in Singapore are to contact JPMS or JPMCB Singapore in respect of any matters arising from, or in connection with, the material. **South Africa:** J.P. Morgan Equities South Africa Proprietary Limited and JPMorgan Chase Bank, N.A., Johannesburg Branch are members of the Johannesburg Securities Exchange and are regulated by the Financial Services Conduct Authority (FSCA). **Taiwan:** J.P. Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. Material relating to equity securities is issued and distributed in Taiwan by J.P. Morgan Securities (Taiwan) Limited, subject to the license scope and the applicable laws and the regulations in Taiwan. According to Paragraph 2, Article 7-1 of Operational Regulations Governing Securities Firms Recommending Trades in Securities to Customers (as amended or supplemented) and/or other applicable laws or regulations, please note that the recipient of this material is not permitted to engage in any activities in connection with the material that may give rise to conflicts of interests, unless otherwise disclosed in the "Important Disclosures" in this material. **Thailand:** This material is issued and distributed in Thailand by JPMorgan Securities (Thailand) Ltd., which is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission, and its registered address is 3rd Floor, 20 North Sathorn Road, Silom, Bangkok, Bangkok 10500. **UK:** Unless specified to the contrary, research is distributed in the UK by J.P. Morgan Securities plc ("JPMS plc") which is a member of the London Stock Exchange and is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. JPMS plc is registered in England & Wales No. 2711006, Registered Office 25 Bank Street, London, E14 5JP. This material is directed in the UK only to: (a) persons having professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) (Order) 2005 ("the FPO"); (b) persons outlined in article 49 of the FPO (high net worth companies, unincorporated associations or partnerships, the trustees of high value trusts, etc.); or (c) any persons to whom this communication may otherwise lawfully be made; all such persons being referred to as "UK relevant persons". This material must not be acted on or relied on by persons who are not UK relevant persons. Any investment or investment activity to which this material relates is only available to UK relevant persons and will be engaged in only with UK relevant persons. Research issued by JPMS plc has been prepared in accordance with JPMS plc's policy for prevention and avoidance of conflicts of interest related to the production of Research which can be found at the following link: [J.P. Morgan EMEA - Research Independence Policy](#). **U.S.:** J.P. Morgan Securities LLC ("JPMS") is a member of the NYSE, FINRA, SIPC, and the NFA. JPMorgan Chase Bank, N.A. is a member of the FDIC. Material published by non-U.S. affiliates is distributed in the U.S. by JPMS who accepts responsibility for its content.

**General:** Additional information is available upon request. The information in this material has been obtained from sources believed to be reliable. While all reasonable care has been taken to ensure that the facts stated in this material are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable, JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively J.P. Morgan) make no representations or warranties whatsoever to the completeness or accuracy of the material provided, except with respect to any disclosures relative to J.P. Morgan and the Research Analyst's involvement with the issuer that is the subject of the material. Accordingly, no reliance should be placed on the accuracy, fairness or completeness of the information contained in this material. There may be certain discrepancies with data and/or limited content in this material as a result of calculations, adjustments, translations to different languages, and/or local regulatory restrictions, as applicable. These discrepancies should not impact the overall investment analysis, views and/or recommendations of the subject company(ies) that may be discussed in the material. J.P. Morgan accepts no liability whatsoever for any loss arising from any use of this material or its contents, and neither J.P. Morgan nor any of its respective directors, officers or employees, shall be in any way responsible for the contents hereof, apart from the liabilities and responsibilities that may be imposed on them by the relevant regulatory authority in the jurisdiction in question, or the regulatory regime thereunder. Opinions, forecasts or projections contained in this material represent J.P. Morgan's current opinions or judgment as of the date of the material only and are therefore subject to change without notice. Periodic updates may be provided on companies/industries based on company-specific developments or announcements, market conditions or any other publicly available information. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or projections, which represent only one possible outcome. Furthermore, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions that have not been verified, and future actual results or events could differ materially. The value of, or income from, any investments referred to in this material may fluctuate and/or be affected by changes in exchange rates. All pricing is indicative as of the close of market for the securities discussed, unless otherwise stated. Past performance is not indicative of future results. Accordingly, investors may receive back less than originally invested. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. This material may include views on structured securities, options, futures and other derivatives. These are complex instruments, may involve a high degree of risk and may be appropriate investments only for sophisticated investors who are capable of understanding and assuming the risks involved. The recipients of this material must make their own independent decisions regarding any securities or financial instruments mentioned herein and should seek advice from such independent financial, legal, tax or other adviser as they deem necessary. J.P. Morgan may trade as a principal on the basis of the Research Analysts' views and research, and it may also engage in transactions for its own account or for its clients' accounts in a manner

inconsistent with the views taken in this material, and J.P. Morgan is under no obligation to ensure that such other communication is brought to the attention of any recipient of this material. Others within J.P. Morgan, including Strategists, Sales staff and other Research Analysts, may take views that are inconsistent with those taken in this material. Employees of J.P. Morgan not involved in the preparation of this material may have investments in the securities (or derivatives of such securities) mentioned in this material and may trade them in ways different from those discussed in this material. This material is not an advertisement for or marketing of any issuer, its products or services, or its securities in any jurisdiction.

**Confidentiality and Security Notice:** This transmission may contain information that is privileged, confidential, legally privileged, and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained herein (including any reliance thereon) is STRICTLY PROHIBITED. Although this transmission and any attachments are believed to be free of any virus or other defect that might affect any computer system into which it is received and opened, it is the responsibility of the recipient to ensure that it is virus free and no responsibility is accepted by JPMorgan Chase & Co., its subsidiaries and affiliates, as applicable, for any loss or damage arising in any way from its use. If you received this transmission in error, please immediately contact the sender and destroy the material in its entirety, whether in electronic or hard copy format. This message is subject to electronic monitoring: <https://www.jpmorgan.com/disclosures/email>

**MSCI:** Certain information herein ("Information") is reproduced by permission of MSCI Inc., its affiliates and information providers ("MSCI") ©2024. No reproduction or dissemination of the Information is permitted without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES (INCLUDING MERCHANTABILITY OR FITNESS) AS TO THE INFORMATION AND DISCLAIMS ALL LIABILITY TO THE EXTENT PERMITTED BY LAW. No Information constitutes investment advice, except for any applicable Information from MSCI ESG Research. Subject also to [msci.com/disclaimer](https://www.msci.com/disclaimer)

**Sustainalytics:** Certain information, data, analyses and opinions contained herein are reproduced by permission of Sustainalytics and: (1) includes the proprietary information of Sustainalytics; (2) may not be copied or redistributed except as specifically authorized; (3) do not constitute investment advice nor an endorsement of any product or project; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Sustainalytics is not responsible for any trading decisions, damages or other losses related to it or its use. The use of the data is subject to conditions available at <https://www.sustainalytics.com/legal-disclaimers>. ©2024 Sustainalytics. All Rights Reserved.

"Other Disclosures" last revised October 05, 2024.

---

**Copyright 2024 JPMorgan Chase & Co. All rights reserved. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan. It is strictly prohibited to use or share without prior written consent from J.P. Morgan any research material received from J.P. Morgan or an authorized third-party ("J.P. Morgan Data") in any third-party artificial intelligence ("AI") systems or models when such J.P. Morgan Data is accessible by a third-party. It is permissible to use J.P. Morgan Data for internal business purposes only in an AI system or model that protects the confidentiality of J.P. Morgan Data so as to prevent any and all access to or use of such J.P. Morgan Data by any third-party.**

Completed 29 Oct 2024 10:09 PM EDT

Disseminated 29 Oct 2024 10:09 PM EDT